Quick Answer
Theravance Biopharma, Inc. reported Earnings Per Share Diluted of $2.06 per share for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +279.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $1.40 (loss) per share | Q2 2020: $1.00 (loss) per share | Q3 2020: $1.16 (loss) per share | Q4 2020: $0.92 (loss) per share | Q1 2021: $1.24 (loss) per share | Q2 2021: $0.80 (loss) per share | Q3 2021: $0.48 (loss) per share | Q4 2021: $0.43 (loss) per share | Q1 2022: $0.34 (loss) per share | Q2 2022: $0.11 (loss) per share | Q3 2022: $12.14 per share | Q4 2022: $0.15 (loss) per share | Q1 2023: $0.35 (loss) per share | Q2 2023: $0.28 (loss) per share | Q3 2023: $0.17 (loss) per share | Q4 2023: $0.17 (loss) per share | Q1 2024: $0.24 (loss) per share | Q2 2024: $0.34 (loss) per share | Q3 2024: $0.26 (loss) per share | Q4 2024: $0.31 (loss) per share | Q1 2025: $0.27 (loss) per share | Q2 2025: $1.08 per share | Q3 2025: $0.07 per share | Q4 2025: $1.15 per share.
- Over the full 7 years of available data (2019 to 2025), Theravance Biopharma, Inc.'s Earnings Per Share Diluted has grown by 148.5%.
- Historical annual values: Fiscal year 2025: $2.06 per share | Fiscal year 2024: $1.15 (loss) per share | Fiscal year 2023: $1.00 (loss) per share | Fiscal year 2022: $11.85 per share | Fiscal year 2021: $2.87 (loss) per share | Fiscal year 2020: $4.46 (loss) per share | Fiscal year 2019: $4.25 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: